Discover the best Joint & Muscle Pain Relief in Best Sellers. Health & Personal Care Household Supplies Vitamins & Diet Supplements Baby Biofreeze Pain Relief Gel, 4 oz. Nutiva Organic Cold-Pressed Unrefined Hemp Oil, 24 Ounce Turmeric Curcumin Softgels, Qunol with Ultra High Absorption mg, Joint. Nutiva Organic Cold-Pressed Unrefined Hemp Oil, 24 Ounce Majestic Pure Cellulite Cream, 87% Organic, Tight Muscles & Joint and Muscle Pain, Natural. Biofreeze Pain Relief Gel, 4 oz. Tube Outback All-Natural Pain Relief – 50mL Roll-On ( fl oz) – Topical Oil · out of 5 stars Premium Organic Hemp Extract Cream For Pain Relief - mg of Hemp Extract - All Natural BC Aspirin Fast Pain Relief Powder | Relieves Headache & Body Aches | 50 Powders |.
Oil Hemp Oil 1000mg Hemp 4oz Muscle #14 iVitamins’ Best for Aches:
Salonpas Pain Relieving Patch - Patches. Get to Know Us. English Choose a language for shopping. Amazon Music Stream millions of songs. Amazon Advertising Find, attract, and engage customers. Amazon Drive Cloud storage from Amazon. Alexa Actionable Analytics for the Web. AmazonGlobal Ship Orders Internationally. Amazon Inspire Digital Educational Resources. Amazon Rapids Fun stories for kids on the go. Amazon Restaurants Food delivery from local restaurants. ComiXology Thousands of Digital Comics.
East Dane Designer Men's Fashion. Shopbop Designer Fashion Brands. Withoutabox Submit to Film Festivals. Amazon Renewed Refurbished products with a warranty. For gastrostomy and nasoenteric tubes, the mean amount of drug recovered ranged from A simple and accurate procedure was developed for dissolving risedronate tablets in water to prepare a liquid formulation for administration orally or through feeding tubes.
The effect of dosing regimen on the pharmacokinetics of risedronate. Aims To examine the effect of timing of a risedronate dose relative to food intake on the rate and extent of risedronate absorption following single-dose, oral administration to healthy male and female volunteers.
Methods A single-dose, randomized, parallel study design was conducted with volunteers assigned to four treatment groups 31 or 32 subjects per group, subjects total. Each subject was orally administered 30 mg risedronate. Group 1 was fasted for 10 h prior to and 4 h after dosing fasted group ; Groups 2 and 3 were fasted for 10 h and were dosed 1 and 0.
Blood and urine samples were collected for h after dosing. Pharmacokinetic parameters were estimated by simultaneous analysis of risedronate serum concentration and urinary excretion rate-time data. Conclusions The comparable extent of risedronate absorption when administered either 0.
This flexibility in the timing of risedronate administration may provide patients an alternative means to achieve the desired efficacy while maintaining their normal daily routine. Purpose Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer. Patients and Methods Premenopausal women undergoing chemotherapy for breast cancer were treated with oral calcium mg and vitamin D U daily and randomly assigned to receive oral risedronate 35 mg weekly or placebo, with all these therapies beginning within a month of the start of chemotherapy.
Most chemotherapy regimens included anthracyclines, taxanes, or cyclophosphamide. Bone mineral density BMD was measured at baseline and 1 year. Results A total of women enrolled; women provided BMD data at 1 year. There was no difference in the mean change or percent change in LS BMD between groups, with a loss of 4. Loss of BMD at the femoral neck and total hip were also similar between treatment groups.
Risedronate was well tolerated, with no significant differences in adverse events compared with placebo, except that arthralgias and chest pain were worse in those receiving the placebos. Conclusion Risedronate did not prevent bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer. Effects of glucosamine and risedronate alone or in combination in an experimental rabbit model of osteoarthritis. Background The osteoarthritis OA treatment in humans and in animals is a major orthopaedic challenge because there is not an ideal drug for preserving the joint structure and function.
The aim of this study was to assess the effects of the treatment with oral glucosamine and risedronate alone or in combination on articular cartilage, synovial membrane and subchondral bone in an experimental rabbit model of OA. Osteoarthritis was surgically induced on one knee of 32 New Zealand White rabbits using the contralateral as healthy controls. Animal were divided in four groups of oral treatment: Following sacrifice femurs were removed and osteochondral cylinders and synovial membrane were obtained for its histological and micro-CT evaluation.
Results Sample analysis revealed that the model induced osteoarthritic changes in operated knees. OA placebo group showed a significant increase in cartilage thickness respect to the control and inflammatory changes in synovial membrane; whereas subchondral bone structure and volumetric bone mineral density remained unchanged. All the treated animals showed an improvement of the cartilage swelling independent of the drug used.
Treatment with glucosamine alone seemed to have no effect in the progression of cartilage pathology while risedronate treatment had better results in superficial fibrillation and in resolving the inflammatory changes of the tissues, as well as modifying the orientation of trabecular lattice.
The combination of both compounds seemed to have additive effects showing better results than those treated with only one drug. Conclusions The results of this animal study suggested that glucosamine sulfate and risedronate treatment alone or in combination may be. Data on treatment of glucocorticoid-induced osteoporosis GIO in men are scarce. Computed tomography scans were performed at 0, 6, and 18 months.
A mixed model repeated measures analysis was performed to compare changes from baseline between groups. Mean age was Median GC dose and duration were 8. At 18 months, trabecular BMD had significantly increased for both treatments, with significantly greater increases with teriparatide Vertebral strength increases at 18 months were significant in both groups teriparatide: In conclusion, in this. Treatment of bone loss in osteopenic patients with Crohn's disease: Osteoporosis and fractures are frequently encountered in patients with Crohn's disease.
In order to prevent fractures, treatment with bone protecting drugs appears warranted early in the course of bone disease when bone loss is not yet prominent. We therefore aimed to demonstrate a beneficial effect on bone density of the bisphosphonate risedronate in osteopenic Crohn's disease patients.
This double-blind, placebo-controlled randomised trial of risedronate with calcium and vitamin D supplementation was performed in osteopenic Crohn's disease patients. Of consenting patients, were randomised 67 placebo and 64 risedronate. Patient characteristics were similar in both groups, although the risedronate group was slightly heavier body mass index Bone mineral density at lumbar spine increased 0.
The mean increase in total hip bone mineral density was 0. Fracture prevalence and incidence were similar. Change of T-scores and concentrations of bone turnover markers were consistent with a beneficial effect of risedronate when compared with placebo.
No serious unexpected suspected adverse events were observed. For permission to use. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: Summary The RisedronatE and ALendronate REAL study provided a unique opportunity to conduct cost-effectiveness analyses based on effectiveness data from real-world clinical practice.
Using a published osteoporosis model, the researchers found risedronate to be cost-effective compared to generic or brand alendronate for the treatment of Canadian postmenopausal osteoporosis in patients aged 65 years or older. Introduction The REAL study provides robust data on the real-world performance of risedronate and alendronate.
The study used these data to assess the cost-effectiveness of brand risedronate versus generic or brand alendronate for treatment of Canadian postmenopausal osteoporosis patients aged 65 years or older. Methods A previously published osteoporosis model was populated with Canadian cost and epidemiological data, and the estimated fracture risk was validated. Effectiveness data were derived from REAL and utility data from published sources. The incremental cost per quality-adjusted life-year QALY gained was estimated from a Canadian public payer perspective, and comprehensive sensitivity analyses were conducted.
The results were most sensitive to treatment duration and effectiveness. Conclusions The REAL study provided a unique opportunity to conduct cost-effectiveness analyses based on effectiveness data taken from real-world clinical practice.
Androgen deprivation therapy ADT has been used as an adjuvant treatment to radiation therapy RT for the management of locally advanced prostate carcinoma. The objective of this clinical trial was to evaluate the efficacy of risedronate for the prevention of BMD loss in nonmetastatic prostate cancer patients undergoing RT plus 2 to 3 years of ADT.
A double-blinded, placebo-controlled, randomized trial was conducted for nonmetastatic prostate cancer patients receiving RT plus 2 to 3 years of ADT. Patients were randomized 1: The primary endpoints were the percent changes in the BMD of the lumbar spine at 1 and 2 years from baseline, measured by dual energy x-ray absorptiometry. Analyses of the changes in BMD and bone turnover biomarkers were carried out by comparing mean values of the intrapatient changes between the 2 arms, using standard t tests.
One hundred four patients were accrued between and , with 52 in each arm. The placebo had a significant increase in serum bone turnover biomarkers compared with the risedronate. Weekly oral risedronate prevented BMD loss at 2 years and resulted in significant suppression of bone turnover biomarkers for 24 months for patients receiving RT plus 2 to 3 years of ADT.
In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada. Tablets were inspected for colour and appearance.
Disintegration onset time was also evaluated. The mean disintegration onset time values for the generic risedronate 35 mg tablets ranged from 2 to 29 seconds, and the mean disintegration completion times ranged from 81 to seconds.
Four out of the five generic tablets tested had shorter disintegration onset times than the branded product; two of the generic tablet products had very fast disintegration onset times i. Disintegration completion time for all five generic products tested was longer than that observed for the branded product; two generic products had disintegration completion time values five to six times longer than the branded product.
Differences in the in vitro disintegration times were observed between the generic risedronate 35 mg tablets commercially available in Canada and the branded product, ACTONEL. The rapid disintegration onset times of two generic products may be important as this could increase the possibility of drug exposure in both the mouth and the esophagus during swallowing, resulting in unwanted localized irritation.
Until such studies are completed it may be important to be aware of such in vitro disintegration differences when evaluating patients with newly presenting upper gastrointestinal complaints upon being switched from the branded product to generic formulations. Inhibitory effects of a bisphosphonate risedronate on experimental periodontitis in rats. The present study was designed to examine whether systemic administration of a bisphosphonate, risedronate , could prevent alveolar bone resorption in rats with experimental periodontitis.
On Day 1, an elastic ring was placed around the neck of the right mandibular 1st molar to induce inflammatory periodontitis. The animals were given daily injections of either 0. Histological examinations and determination of bone mineral density in the interdental area between the 1st and 2nd molars with an image analyzer revealed that the presence of the elastic ring induced a loss of attachment and bone resorption in the control group.
Vigorous bone resorption, with appearance of a large number of osteoclasts, was observed in the interdental and bifurcation areas. In the experimental groups, however, the resorption of alveolar bone and the loss of bone mineral content in these areas were prevented in a dose-dependent fashion, especially at doses of 1.
Many osteoclasts were detached from the surface of the alveolar bone and had degenerated appearances, such as rounded shapes, loss of polarity and pyknosis. These results suggest that administration of risedronate is effective in preventing bone resorption in periodontitis. Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome. Steroid-induced osteoporosis is a serious adverse effect of this drug.
Patients with MCNS were randomly assigned to two groups, the risedronate 2. All the patients had received PSL and the clinical characteristics were compared between the two groups at baseline and at 12 months. A significant decrease of the mean bone mineral density BMD of the lumbar spine from 0. No significant differences in the results of other biochemical tests performed at the baseline and at 12 months were observed between the two groups.
The likelihood of development of steroid-induced osteoporosis was influenced by the cumulative dose of PSL, the mean BMD at the baseline, occurrence of disease relapse, and risedronate therapy. Risedronate appears to be effective in preventing steroid-induced osteoporosis. Improvement in bone properties by using risedronate adsorbed hydroxyapatite novel nanoparticle based formulation in a rat model of osteoporosis. A superior drug formulation capable of achieving efficient osteogenesis is in imperative demand for the treatment of osteoporosis.
In the present study we investigated the potential of using novel risedronate -hydroxyapatite HA nanoparticle based formulation in an animal model of established osteoporosis. Nanoparticles of HA loaded with risedronate NHLR of various sizes nm were generated for bone targeted drug delivery. One month after drug administration, the left tibia and femur were tested for bone mechanical properties and histology, respectively. In the right femur, bone density was measured by method based on Archimedes principle and bone porosity analyses were performed using X-ray imaging.
The results strongly suggest that the NHLR, which is a novel nanoparticle based formulation, has a therapeutic advantage over risedronate sodium monotherapy for the treatment of osteoporosis in a rat model of postmenopausal osteoporosis. The efficacy and safety of weekly mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: Oral risedronate is effective in the treatment of postmenopausal osteoporosis when administered daily, weekly, or monthly.
In this 1-year, randomized, double-blind, multicenter study we compared the weekly mg and daily 5-mg risedronate dosing regimens in the treatment of Chinese postmenopausal women with osteoporosis or osteopenia. All subjects in the weekly group and subjects in the daily group completed the study. The incidences of clinical adverse events were The weekly mg and daily 5-mg risedronate dosing regimens during 1 year of follow-up show similar efficacy in improving BMDs and biochemical markers of bone turnover in Chinese postmenopausal women with osteoporosis or osteopenia.
Moreover, the two dosing regimens exhibit similar safety and tolerability. Effect of risedronate on bone in renal transplant recipients. Bisphosphonates may prevent or treat the bone loss promoted by the immunosuppressive regimens used in renal transplantation. Risedronate is a commonly used third-generation amino-bisphosphonate, but little is known about its effects on the bone health of renal transplant recipients.
We randomly assigned 42 new living-donor kidney recipients to either 35 mg of risedronate weekly or placebo for 12 months. We obtained bone biopsies at the time of renal transplant and after 12 months of protocol treatment. Treatment with risedronate did not affect bone mineral density BMD in the overall cohort.
In subgroup analyses, it tended to preserve BMD in female participants but did not significantly affect the BMD of male participants. Risedronate did associate with increased osteoid volume and trabecular thickness in male participants, however. There was no evidence for the development of adynamic bone disease. In summary, further study is needed before the use of prophylactic bisphosphonates to attenuate bone loss can be recommended in renal transplant recipients.
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. AIMS To evaluate the association between noncompliance with alendronate and risedronate and the risk of nonvertebral osteoporotic fracture in community-dwelling elderly women. A woman was noncompliant if she had a medication possession ratio MPR RESULTS Among the 30 women included in the cohort, nonvertebral fracture cases were identified and were matched to 20 controls.
Few studies have specifically evaluated the impact of noncompliance with alendronate or risedronate on the incidence of osteoporotic fractures in community-dwelling elderly women. Comparative gastrointestinal safety of weekly oral bisphosphonates. Summary Weekly bisphosphonates are the primary agents used to treat osteoporosis.
Although these agents are generally well tolerated, serious gastrointestinal adverse events, including hospitalization for gastrointestinal bleed, may arise.
We compared the gastrointestinal safety between weekly alendronate and weekly risedronate and found no important difference between new users of these agents.
Introduction Weekly bisphosphonates are the primary agents prescribed for osteoporosis. We examined the comparative gastrointestinal safety between weekly bisphosphonates. Methods We studied new users of weekly alendronate and weekly risedronate from June to August among enrollees in a state-wide pharmaceutical benefit program for seniors.
Our primary outcome was hospitalization for upper gastrointestinal bleed. Secondary outcomes included outpatient diagnoses for upper gastrointestinal disease, symptoms, endoscopic procedures, use of gastroprotective agents, and switching between therapies.
We used Cox proportional hazard models to compare outcomes between agents within days of treatment initiation, adjusting for propensity score quintiles.
We also examined composite safety outcomes and stratified results by age and prior gastrointestinal history. We observed 31 hospitalizations for upper gastrointestinal bleed 0. Adjusting for covariates, there was no difference in hospitalization for upper gastrointestinal bleed among those treated with risedronate compared with alendronate HR, 1. Risedronate switching rates were lower; otherwise, no differences were observed for secondary or composite outcomes.
Conclusions We found no important difference in gastrointestinal safety between weekly oral bisphosphonates. Introduction Irradiation of normal, non-malignant bone during cancer therapy can lead to atrophy and increased risk of fracture at several skeletal sites, particularly the hip.
This bone loss has been largely attributed to damaged osteoblasts. Little attention has been given to increased bone resorption as a contributor to radiation-induced osteoporosis. Our aims were to identify if radiation increases bone resorption resulting in acute bone loss, and if bone loss could be prevented by administering risedronate.
Calcein injections were administered 7 and 2 days before sacrifice. Bones were collected 1, 2, and 3 weeks after exposure. MicroCT analysis was performed at 3 sites: Osteoclasts were identified from TRAP-stained histological sections. Dynamic histomorphometry of cortical and trabecular bone was performed. Circulating TRAP5b and osteocalcin concentrations were quantified. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis VERO: No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome.
We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis. The primary outcome was new radiographic vertebral fractures. Secondary, gated outcomes included new and worsened radiographic vertebral fractures, clinical fractures a composite of non-vertebral and symptomatic vertebral , and non-vertebral fractures.
This study is registered with ClinicalTrials. We enrolled patients in each group. Among post-menopausal women with severe osteoporosis, the risk of new vertebral and clinical fractures is significantly lower in patients receiving teriparatide than in those receiving risedronate.
Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial The aim of this study was to investigate the efficacy of concurrent treatment with vitamin K 2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis and to explore subsets of patients for which concurrent treatment is particularly efficacious. The primary end point was the incidence of any fracture vertebral and nonvertebral.
The secondary end points were bone mineral density, height, undercarboxylated osteocalcin concentration, quality of life, and safety. Over a 2-year follow-up, vertebral or nonvertebral fractures occurred in or 22 sites respectively among patients in the risedronate and vitamin K 2 group and in or 26 sites respectively among patients in the risedronate alone group.
The rates of any incident fracture were similar between the two groups incidence rate ratio 1. There were no differences in the degree of increase in bone mineral density between the two groups. Undercarboxylated osteocalcin concentration decreased from 5.
No unknown adverse drug reactions were reported. In conclusion, concurrent treatment with vitamin K 2 and risedronate was not efficacious compared with monotherapy with risedronate in terms of fracture prevention.
Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: Delayed esophageal transit or disintegration of oral bisphosphonate tablets before they enter the stomach may be of concern with respect to iatrogenic complications among patients receiving longterm treatment. Different formulations of generic bisphosphonate tablets meeting regulatory requirements may have substantial differences in pharmaceutical attributes from the branded product that may result in different characteristics during esophageal transit.
The primary objective of this study was to evaluate and compare esophageal transit times and in vivo disintegration of 3 bisphosphonate formulations, one branded and the others generic, that are commercially available in Canada and the United Kingdom.
Each subject received a single oral dose of a branded risedronate sodium mg tablet and 2 generic formulations of alendronic acid mg tablets Novopharm Limited, Toronto, Canada, and Teva UK Limited, Morley, United Kingdom in both the erect and semisupine 45 degrees positions.
Although the products are labeled to be taken in the erect position, the semisupine position was included to simulate dosing in bedridden patients. Subjects took tablets with 30 mL of water in the morning after an overnight fast. The tablets were radiolabeled with technetiumm ion-exchange resins to enable visualization and measurement of esophageal transit time and disintegration using a gamma camera.
Dynamic scintigraphic images were obtained for a total of 10 minutes: This was a mechanistic study and tolerability was not assessed. The study was conducted in 20 healthy white female subjects with a mean age of 62 years range, years.
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. There is a high incidence of hip fractures in patients with Parkinson disease PD. Bone mineral density BMD is decreased in patients with PD, correlating with the immobilization-induced bone resorption and hypovitaminosis D with compensatory hyperparathyroidism. To evaluate the effectiveness of risedronate , an inhibitor of bone resorption, on osteoporosis and the risk of hip fractures in elderly men with PD.
This was a 2-year, randomized, double-blind, placebo-controlled trial. In a prospective study of patients with PD, patients received a daily dose of 2. Incidence of hip fractures was compared between the two groups. Nine patients sustained hip fractures in the placebo group, and three hip fractures occurred in the risedronate group. The relative risk of a hip fracture in the risedronate group vs the placebo group was 0.
BMD increased by 2. Treatment with risedronate and vitamin D2 increases bone mineral density in elderly men with Parkinson disease and reduces the risk of hip fractures. Methanol poisoning results in neurological complications including visual disturbances, bilateral putaminal hemorrhagic necrosis, parkinsonism, cerebral edema, coma, or seizures. Almost all reported cases of methanol poisoning are caused by oral ingestion of methanol.
However, recently there was an outbreak of methanol poisoning via non- oral exposure that resulted in severe neurological complications to a few workers at industrial sites in Korea. We present 3 patients who had severe neurological complications resulting from non- oral occupational methanol poisoning. Even though initial metabolic acidosis and mental changes were improved with hemodialysis, all of the 3 patients presented optic atrophy and ataxia or parkinsonism as neurological complications resulting from methanol poisoning.
In order to manage it adequately, as well as to prevent it, physicians should recognize that methanol poisoning by non- oral exposure can cause neurologic complications. The manufacturers of oral bisphosphonates alendronate, risedronate recommend avoiding use of these drugs in patients with renal impairment.
However, many patients who have osteoporosis or who are at risk of fracture are elderly and may have renal impairment. This situation poses a quandary for clinicians in deciding how best to manage osteoporosis in this high-risk population. To synthesize published evidence regarding the use and safety of oral bisphosphonates for patients with impaired renal function. The following databases were searched up to October The following key words and terms were used for the searches: The manufacturers of Fosamax and Actonel were asked to provide information about use of their products in patients with renal impairment, including unpublished pharmacokinetic studies or reports of adverse drug events.
The search yielded 2 post hoc analyses of safety data, 1 case—control study, 1 case series, 4 retrospective chart analyses, and 2 prospective studies.
Increased renal damage occurred in some individuals with underlying renal disorders, as described in case reports. Although the literature is limited, there is evidence that alendronate and risedronate are well tolerated and effective when used by individuals with renal impairment. Further research is required to confirm the benefits and risks of using these medications in patients with renal impairment.
Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: Orally administered bisphosphonate drugs i. However, only alendronate and risedronate have proven efficacy in reducing the risk of hip fracture. We sought to examine the comparative effectiveness of orally administered bisphosphonate drugs in reducing hip fractures among older adults.
We identified new users of orally administered bisphosphonate drugs in British Columbia and Ontario between and We used province- and sex-specific propensity score-matching strategies to maximize comparability between exposure groups. We used Cox proportional hazards models to compare time-to-hip fracture within 1 year of treatment between exposures by sex in each province.
Our secondary analyses considered hip fracture rates within 2 and 3 years' follow-up. We used alendronate as the reference for all comparisons and pooled provincial estimates using random effects variance-weighted meta-analysis.
We found little difference in fracture rates between men pooled hazard ratio [HR] 0. We similarly identified little difference in fracture rates between women taking etidronate and those taking alendronate pooled HR 1. However, we identified lower rates of hip fracture among men taking etidronate relative to alendronate pooled HR 0. Results extended to 2 and 3 years' follow-up were similar. However, with 3 years' follow-up, rates of hip fracture were lower among women in British Columbia who had taken alendronate.
We identified little overall difference between alendronate and risedronate in reducing the risk of hip fracture in men or women. Our finding that etidronate is associated with lower fracture risk among men is likely due to. The efficiency of risedronate in reducing bone resorption after total hip arthroplasty: Recently risedronate is suggested to be effective for the prevention and treatment of for osteoporosis in total hip arthroplasty. This meta-analysis aimes to evaluate the efficacy of risedronate in reducing femoral periprosthetic bone mineral density loss in patients undergoing primary total hip arthroplasty.
Only randomized controlled trial RCT were included. Meta-analysis was performed using Stata The outcome measures included periprosthetic bone mineral density, length of stay and adverse effects. Four RCTs including patients met the inclusion criteria. In addition, no severe adverse events were identified. Future trials of risedronate treatment after THA should focus on clinically relevant end points such as the risks of fracture and revision arthroplasty.
Comparative permeability studies with radioactive and nonradioactive risedronate sodium from self-microemulsifying drug delivery system and solution. The solubility of RSD was determined in different vehicles. Phase diagrams were constructed to determine the optimum concentration of oil, surfactant, and cosurfactant.
After the treatment, we determined the longitudinal bone growth rate, the qualitative appearance of the primary spongiosa PS , and the static and dynamic bone histomorphometry of the secondary spongiosa SS of the proximal tibial metaphysis PTM by examining undecalcified longitudinal sections after double fluorescent labeling. The relative effects of these treatments on longitudinal bone growth were ranked as follows: The density of the PS was ranked as follows: The increase in density of the PS was the result of stimulated longitudinal growth and the action of bisphosphonate.
Bone mass in the SS was ranked as follows: However, PGE2 alone and its cotreatment with Ris accumulated bone by different tissue mechanisms. PGE2 alone created new bone by increasing activation frequency 8.
Efficacy on the risk of vertebral fracture with administration of once-weekly Currently, the only available evidence for the efficacy of once-weekly We performed a week prospective, longitudinal, observational study to determine the efficacy of the We also calculated the change in bone mineral density of the lumbar spine L BMD and urinary N-telopeptide of type I collagen u-NTX , and assessed the incidence of adverse drug reactions and the drug adherence rate.
Data from patients were available for analysis of vertebral fracture prevention. Compared to baseline values, L BMD increased by 6. Oral challenges with four apple cultivars result in significant differences in oral allergy symptoms.
We analyzed the hypoallergenic potential of a recently bred apple selection with unusually low content of Mal d 1, using an oral challenge model with three additional apple cultivars for comparison. Sixty-six birch pollen-allergic individuals with a history of oral allergy syndrome after apple intake were subjected to a double-blind oral provocation with two apple cultivars B: Thirteen also tested two other apple cultivars 'Ingrid Marie' and 'Gloster'. Three doses were given consecutively, 30 min apart: A final assessment was conducted 30 min after the last intake.
Oral symptoms were graded from 0 to 5. Total oral symptom score TOS included all scores for each cultivar at all time points. TOS values were higher in females and increased with increasing age of the individuals when challenged with 'Discovery'. Among the 13 individuals who tested all four cultivars, B: This was also the case after the third dose compared to 'Ingrid Marie' and 'Gloster', and again 30 min after the last intake compared to each of the other three cultivars, as well as a higher TOS compared to each of the other three cultivars all p The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease AD , who are prone to falls and have osteoporosis.
We previously found that deficiency of hydroxyvitamin D and compensatory hyperparathyroidism cause reduced bone mineral density in female patients with AD. We address the possibility that treatment with risedronate sodium and ergocalciferol plus calcium supplementation may reduce the incidence of nonvertebral fractures in elderly women with AD.
A total of elderly women with AD were randomly assigned to daily treatment with 2. At baseline, patients of both groups showed hydroxyvitamin D deficiency with compensatory hyperparathyroidism. During the study period, bone mineral density in the risedronate group increased by 4.
Vertebral fractures occurred in 29 patients 24 hip fractures in the control group and 8 patients 5 hip fractures in the risedronate group. The relative risk in the risedronate group compared with the control group was 0. Elderly patients with AD hypovitaminosis D are at increased risk for hip fracture. Treatment with risedronate and ergocalciferol may be safe and effective in reducing the risk of a fracture in elderly patients with AD. Teriparatide TPTD , a recombinant human parathyroid hormone N-terminal fragment , is a widely used bone anabolic drug for osteoporosis.
Sequential treatment with antiresorptives such as bisphosphonates after TPTD discontinuation is generally recommended. However, relative effects of bisphosphonates have not been determined. Female Sprague Dawley rats were divided into one sham-operated and eight ovariectomized groups. Sp compared to ALN in the fourth lumbar vertebra as well as in greater stiffness in compression test.
Further studies are necessary to determine clinical relevance of these findings to fracture rate. Fabrication and physicochemical characterization of porous composite microgranules with selenium oxyanions and risedronate sodium for potential applications in bone tumors. Nanocrystalline hydroxyapatite containing selenite ions SeHA; 9. Risedronate sodium RIS was introduced to the obtained spherical microgranules of a size of about 1. The analysis made using 13 C and 31 P cross-polarization magic angle spinning nuclear magnetic resonance confirmed the presence of RIS and its interaction with calcium ions.
Then, the release of selenium inductively coupled plasma optical emission spectrometry and RIS high-performance liquid chromatography from microgranules was examined. Moreover, cytotoxicity of fabricated granules was assessed by MTT test.
Selenium release was biphasic: The study showed that the method of obtaining microgranules containing RIS significantly affects its release profile. Performed cytotoxicity test revealed that fabricated granules had high antitumor activity against osteosarcoma cells. However, because of the "burst release" of selenium during the first 10 h, the granules significantly reduced viability of normal osteoblasts as well.
The analysis made using 13C and 31P cross-polarization magic angle spinning nuclear magnetic resonance confirmed the presence of RIS and its interaction with calcium ions. Oral Health in Patients taking Psychotropic Medications: Results from a Pharmacy-Based Pilot Study. Objectives Individuals with mental illness face an increased risk of oral disease compared to those without mental illness.
The goals of this study were to examine the self-reported oral health and dental access of individuals filing psychotropic medication prescriptions; and to determine whether pharmacy patients would choose to speak with a pharmacist about their oral health if given the option to do so.
Design Pharmacists across 6 community pharmacies within a local chain identified and surveyed adult patients filling prescriptions for psychotropic medications. Surveys included questions about oral health, dry mouth, and dental care utilization. Setting Six community pharmacy locations.
Main Outcome Measures Self-reported oral health, dental utilization, desire to discuss oral health with a pharmacist. One in four While dry mouth and poor oral health were common in this sample of individuals taking psychotropic medications, this did not consistently translate into information seeking regarding oral health.
Future research will focus on pharmacist. Perioperative alendronate, risedronate , calcitonin and indomethacin treatment alters femoral stem fixation and periprosthetic bone mineral density in ovariectomized rats. Many factors affect implant stability and periprosthetic bone mineral density BMD following total joint arthroplasty. We asked whether perioperative alendronate, risedronate , calcitonin and indomethacine administration altered 1 femoral stem shear strength and periprosthetic bone mineral density BMD in ovariectomized rats and 2 whether there were differences in the effect of these drugs.
Thirty overiectomized rats were divided into five groups and implanted with intramedullary mini-cortical screws in the femur. Four groups were treated with alendronate, risedronate , salmon calcitonin and indomethacin for 4 weeks preoperatively and 8 weeks postoperatively. Although alendronate and risedronate increased the periprosthetic BMD more than calcitonin, they did not alter implant fixation compared to calcitonin.
Indomethacin significantly decreased the BMD around the stem and implant stability compared to all other groups. This study showed that perioperative treatment with bisphosphonates and calcitonin improved the BMD around the stems and implant stability. Although bisphosphonates increased the BMD more than calcitonin, there was no difference in implant stability. Indomethacin markedly decreased the periprosthetic BMD and implant stability.
The main clinical significance of our study was the finding about the need to strictly avoid long-term use of high-dose nonsteroidal antiinflammatory drugs for patients who have major joint arthritis and a previous history of arthroplasty. Background Periodontal diseases are inflammatory processes that occur following the influx of neutrophils into the periodontal tissues in response to the subgingival bacterial biofilm.
Current literature suggests that while neutrophils are protective and prevent bacterial infections, they also appear to contribute to damage of the periodontal tissues. In the present study we compare the gene expression profile changes in neutrophils as they migrate from the circulation into the oral tissues in patients with chronic periodontits and matched healthy subjects.
We hypothesized that oral neutrophils in periodontal disease patients will display a disease specific transcriptome that differs from the oral neutrophil of healthy subjects. Methods Venous blood and oral rinse samples were obtained from healthy subjects and chronic periodontitis patients for neutrophil isolation.
Results and Discussion Chronic periodontitis patients presented with increased recruitment of neutrophils to the oral cavity. Gene expression analysis revealed differences in the expression levels of genes from several biological pathways. Using hierarchical clustering analysis, we found that the apoptosis network was significantly altered in patients with chronic inflammation in the oral cavity, with up-regulation of pro-survival members of the Bcl-2 family and down-regulation of pro-apoptosis members in the same compartment.
Additional functional analysis confirmed that the percentages of viable neutrophils are significantly increased in the oral cavity of chronic periodontitis patients. Conclusions Oral neutrophils from patients with periodontal disease displayed an altered transcriptome following migration into the oral tissues.
This resulted in a pro-survival neutrophil phenotype in chronic periodontitis patients. The mobile phase consisted of formate buffer solution pH 3. Stability characteristics of SR were evaluated by performing stress test studies. The validation parameters such as linearity, sensitivity, accuracy, precision and selectivity were found to be highly satisfactory. Linear responses were observed in standard and in fortified placebo solutions.
Recovery studies showed good results for all the examined compounds from The high stability of standard and sample solutions at room temperature means an undoubted advantage of the method allowing the simultaneous preparation of many samples and consecutive chromatographic analyses by using an autosampler. The developed stability indicating.
Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women. In the United States, over 34 million American post-menopausal women have low bone mass osteopenia which increases their risk of osteoporosis and fractures. Calcium, vitamin D and exercise are recommended for prevention of osteoporosis, and bisphosphonates BPs are prescribed in women with osteoporosis. BPs may also be prescribed for women with low bone mass, but are more controversial due to the potential for adverse effects with long-term use.
A bone loading exercise program high-impact weight bearing and resistance training promotes bone strength by preserving bone mineral density BMD , improving bone structure, and by promoting bone formation at sites of mechanical stress. Our central hypothesis is that improvements in bone strength will be greater in subjects randomized to the Exercise group compared to subjects in either Control or Risedronate groups.
Results of this study could be used in. Star-shaped poly oligoethylene glycol copolymer-based gels: Thermo-responsive behaviour and bioapplicability for risedronate intranasal delivery.
The aim of this work was to obtain an intranasal delivery system with improved mechanical and mucoadhesive properties that could provide prolonged retention time for the delivery of risedronate RS. RS was trapped in the selected gel-forming solutions at a concentration of 0.
The pH, rheological properties, in vitro drug release, ex vivo permeation as well as mucoadhesion were also examined. MTT assays were conducted to verify nasal tolerability of the developed formulations.
Initial in vivo studies were carried out to evaluate anti-osteoporotic activity in a glucocorticoid induced osteoporosis model in rats. Moreover, sustained release of RS, augmented permeability and marked anti-osteoporotic efficacy as compared to intranasal IN and intravenous IV RS solutions were realized. The combined results show that the in situ gels should have promising application as nasal drug delivery systems.
Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease. Minodronate is a nitrogen-containing bisphosphonate that is commercially available for the treatment of osteoporosis in Japan.
Preclinical studies demonstrated that minodronate is at least 10 times more potent than alendronate in inhibiting bone resorption in vivo. A high incidence of fractures, particularly of the hip, represents an important problem in Alzheimer disease AD patients who are prone to falls and may have osteoporosis.
A total of elderly patients with AD were assigned to daily treatment with 1. At baseline, patients of both groups showed low hydroxyvitamin D with compensatory hyperparathyroidism. Non-vertebral fractures occurred in 5 patients in the minodronate group and 7 patients in the risedronate group 5 hip fractures; one fracture each at the distal forearm and pelvis. The study medications were well tolerated with relatively few adverse events and were equivalent in reducing the risk of a fracture in elderly patients with AD.
Dental caries is an infectious disease caused by oral acidophilic bacteria feeding on fermentable sugars, e. The frequency of dental caries in Neandertals was very low. This was usually explained as the result of a low-sugar diet. Recent research, however, revealed some regional differences between European and Near Eastern Neandertals, with the latter consuming considerable amounts of plants including highly cariogenic dates.
This discovery, compared with the results of research on genetic diversity of S. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: Efficacy of osteoporosis medication is not well-established among patients taking oral glucocorticoids.
We assessed the efficacy of approved osteoporosis pharmacotherapies in preventing fracture by combining data from randomized controlled trials. Teriparatide, risedronate , and etidronate were associated with decreased vertebral fracture risk. Several osteoporosis drugs are approved for the prevention and treatment of glucocorticoid GC -induced osteoporosis.
However, the efficacy of these treatments among oral GC users is still limited. We aimed to examine the comparative efficacy of osteoporosis treatments among oral GC users. We updated a systematic review through to March to identify all double-blinded randomized controlled trials RCTs that examined osteoporosis treatment among oral GC users. Treatment ranking was estimated using the surface under the cumulative ranking curve SUCRA statistic.
A meta-regression was completed to assess a subgroup effect between patients with prior GC exposures and GC initiators. We identified 27 eligible RCTs examining nine active comparators.
Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a year period: Bisphosphonates are the first-line therapy for the treatment of osteoporosis. In the province of Ontario, the Ontario Drug Benefit Program funds medications for patients aged 65 years and older.
The Ontario Drug Benefit Program has a generic substitution policy that requires lower-cost generic drugs to be dispensed when they are available. However, there is controversy surrounding the efficacy and tolerability of generic bisphosphonates. The objective of this study was to describe patterns in the use of brand-name versus generic formulations when dispensing oral bisphosphonate over a year period. We identified all osteoporotic preparations for alendronate and risedronate that were dispensed through the Ontario Drug Benefit Program from to We stratified our sample into community-dwelling residents and residents in long-term care facilities.
The number of prescriptions dispensed per month were plotted to illustrate trends over time. We also observed a reduction in the number of generic drugs dispensed each time a new brand-name alternative e. The dispensing trends were similar in the community and long-term care settings.
The Ontario Drug Benefit Program generic substitution policy resulted in rapid uptake of generic oral bisphosphonates among seniors in Ontario. However, there was a switch away from generic medications to new brand-name alternatives whenever they were introduced to the formulary. Therefore, some patients continued to use brand-name bisphosphonate despite the availability of generic options.
Efficacy and safety of oral alitretinoin in severe oral lichen planus-- results of a prospective pilot study. Patients with severe oral lichen planus refractory to standard topical treatment currently have limited options of therapy suitable for long-term use. Oral alitretinoin 9-cis retinoic acid was never systematically investigated in clinical trials, although case reports suggest its possible efficacy.
To assess the efficacy and safety of oral alitretinoin taken at 30 mg once daily for up to 24 weeks in the treatment of severe oral lichen planus refractory to standard topical therapy. We conducted a prospective open-label single arm pilot study to test the efficacy and safety of 30 mg oral alitretinoin once daily for up to 24 weeks in severe oral lichen planus.
Ten patients were included in the study. Primary end point was reduction in signs and symptoms measured by the Escudier severity score. Secondary parameters included pain and quality of life scores. Safety parameters were assessed during a follow-up period of 5 weeks.
A substantial response at the end of treatment, i. Therapy was well tolerated. Adverse events were mild and included headache, mucocutaneous dryness, musculoskeletal pain, increased thyroid-stimulating hormone and dyslipidaemia. Alitretinoin given at 30 mg daily reduced disease severity of severe oral lichen planus in a substantial proportion of patients refractory to standard treatment, was well tolerated and may thus represent one therapeutic option for this special group of patients.
Prospective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis.
In addition to the well-described implications of estrogen deficiency in postmenopausal osteoporosis PMO , free radicals are also effective on bone metabolism. The antioxidant vitamins C and E play an important role in the production of collagen, mesenchymal cell differentiation into osteoblasts, and bone mineralization. Therefore, the incidence of osteoporosis and the risk of fractures were decreased with vitamin C and E. It was proposed that free oxygen radicals are responsible for biological aging, atherosclerosis, carcinogenesis, and osteoclastic activity via their negative effects on the cell and DNA.
In this study, we aimed to investigate and compare the levels of free radicals and serum antioxidant activity in patients with PMO and healthy subjects before and after six-month treatment with risedronate , which is an inhibitor of bone resorption. Patients who had received any medications within the last 6 months that could alter bone metabolism were excluded. The patients were reevaluated at the end of the sixth month. There may be an insufficiency in different steps of the enzymatic antioxidant systems in patients with PMO without treatment.
Bisphosphonates are beneficial to women, after menopause, in treatment of gum diseases. In this study, significant improvement in the disease condition was found and that no further progress was noted, and no side effects were reported.
Bisphosphonates can be safely and successfully be used to support oral health procedures. The purpose of this study was to evaluate host modulating effect of bisphosphonate adjunct with the treatment of chronic periodontitis in osteopenic and osteoporotic postmenopausal women.
Twenty-two osteopenic and osteoporotic postmenopausal women with moderate to severe chronic periodontitis were selected for the study. Scaling and root planing were done. There was a significant improvement in all the parameters. There was an increase of 0. Bone density increased by There was no progress in the disease, and further bone loss was not noticed.
Best Pain Relieve Rubs & Ointments - Buying Guide
Discover the best Pain Relief Medications & Treatments in Best Sellers. Children's Motrin Oral Suspension Dye-Free Berry, Ibuprofen, Fever Reducer, 4 Oz Nutiva Organic Cold-Pressed Unrefined Hemp Oil, 24 Ounce . Relief Hemp Cream Mg - Hemp Extract Cream for Inflammation & Sore Muscles - Natural. #14 Best Selling product in Other Natural & Alternative Remedies 2. mg CBD Balm Salve Natural Pain Relief with Lavender Mint EO 4oz Jar . mg Oil Pain Relief OINT Balm Salve All Natural 1 Oz CBD . and uses to mention, from hemorrhoids to psoriasis, muscle aches and joint pain This Salve is the Balm!. See more ideas about Bone strength, Herbalism and Body care. The 7 Best Vitamins for Women to Buy in Good Vitamins For Women, 10 Herb Blend for Herbal Pain Relief, 30 Day Supply: Health & Personal Care .. Here's the solution: Highest potency CBD rich hemp oil available, AND legal in CLA mg.